Sanara MedTech Inc. (SMTI)

From the record

Sanara MedTech Inc.'s filings since 2017 show 5 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2019-03-21); an auditor change (8-K item 4.01, the latest 2021-09-13); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2019-05-16) (its current reports).

From the record

Sanara MedTech Inc.'s 6 filed years say what it did: revenue went from $16 million in fiscal 2020 to $103 million in fiscal 2025, up 45.9% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Sanara MedTech Inc.'s diluted share count grew about 2.9% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Sanara MedTech Inc. lost about 633 cents for every dollar of shareholders' money, and gross profitability: its products earned about 131 cents per dollar of everything the company owns. Leverage: it owed about 92 cents per dollar of assets, and net share issuance: its share count grew 1.6% over the year (the filed statements).

From the record

Sanara MedTech Inc.'s standing among 26 graded names in its industry family: revenue of $103 million in fiscal 2025 ranks in the bottom 48% by size; a net margin of -36.4% ranks in the bottom 44%; revenue growth of 31% a year over the last 3 filed years ranks in the top 17% (its annual reports).

From the record

Sanara MedTech Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Yon, Seth D (Chief Executive Officer, as filed), filing under that title since 2025-09-16, 1.2 years (bottom 3% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 4.9 years (bottom 28%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 43%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Sanara MedTech Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $17 million against debt of $46 million leaves -40.3% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 2.1% of revenue (top 38%); a gross margin of 92.7% (top 2%); research spending of 4.9% of revenue (bottom 20%) (its annual report).

From the record

Sanara MedTech Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 31% a year over the last three filed years against 45.9% over all 6, slowing (bottom 6% of its family); the newest year grew 19% (top 18%); research spending grew 14.6% a year (top 27%); capital spending grew 215.6% a year (top 6%) (its annual reports). Sanara MedTech Inc. reported 2 product lines in fiscal 2025: Soft Tissue Repair Products at $91 million (89%), Bone Fusion Products at $12 million (11%); 2 of 2 grew against the year before (its annual report).

From the record

Sanara MedTech Inc.'s newest year against its own record: revenue of $103 million in fiscal 2025 came in 13.5% below the $119 million its prior three years' pace pointed to (bottom 19% of its family); net income of $38 million against a prior three-year average of $7 million (bottom 2%); a net margin of -36.4% against -11.7% before (bottom 28%) (its annual reports).